The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine

摘要

BackgroundActivating point mutation of the RAS gene has been generally accepted as an oncogenic event in a variety of malignancies. It represents one of the most common genetic alterations in acute myeloid leukemia (AML). However, little is known about its clinical relevance in the treatment outcome for this leukemia.